<DOC>
	<DOCNO>NCT03072238</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety , pharmacokinetics ipatasertib plus abiraterone prednisone/prednisolone compare placebo plus abiraterone prednisone/prednisolone participant metastatic castrate-resistant prostate cancer ( mCRPC ) .</brief_summary>
	<brief_title>Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone , Relative Placebo Plus Abiraterone Plus Prednisone/Prednisolone Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Eastern Collaborative Oncology Group ( ECOG ) performance status 0 1 screen Adequate hematologic organ function within 28 day first study treatment Ability comply study protocol , investigator 's judgment Willingness ability participant ( observer , caregiver ) use electronic device report select study outcome Life expectancy least 6 month Agreement remain abstinent ( refrain heterosexual intercourse ) use contraceptive measure , agreement refrain donate sperm For enrollment China extension cohort , residence People 's Republic China Diseasespecific Histologically confirm prostate adenocarcinoma without neuroendocrine differentiation smallcell feature Consent provide formalinfixed paraffinembedded ( FFPE ) tissue block ( prefer ) minimum 15 ( 20 prefer ) freshly cut unstained tumor slide recently collect , available tumor tissue accompany associated pathology report ( tumor content information , Gleason score , disease stag ) PTEN IHC NGS test protocolmandated secondary exploratory assessment . Cytologic fineneedle aspiration sample acceptable . Tumor tissue bone metastasis subject decalcification acceptable . A valid PTEN IHC result ( per central test ) ( e.g. , participant `` invalid '' `` fail '' PTEN IHC result permit enroll ) Metastatic disease document prior randomization bone lesion bone scan soft tissue disease compute tomography ( CT ) magnetic resonance imaging ( MRI ) Asymptomatic mildly symptomatic form prostate cancer Progressive disease initiate study treatment Ongoing androgen deprivation gonadotropinreleasing hormone ( GnRH ) analog bilateral orchiectomy , serum testosterone &lt; 50 ng/dL ( &lt; 2.0 nmol/L ) within 28 day randomization Inability unwillingness swallow whole pill History malabsorption syndrome condition would interfere enteral absorption Clinically significant history liver disease consistent ChildPugh Class B C , include cirrhosis , current alcohol abuse , current know active infection hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) Need current chronic corticosteroid therapy ( &gt; 10 mg/day prednisone equivalent dose antiinflammatory corticosteroid ) Active infection require intravenous ( IV ) antibiotic within 14 day Day 1 , Cycle 1 Immunocompromised status current know active infection HIV use immunosuppressive therapy condition Major surgical procedure significant traumatic injury within 28 day prior Day 1 , Cycle 1 , anticipation need major surgery study treatment History ventricular dysrhythmias risk factor ventricular dysrhythmias , structural heart disease ( e.g. , severe leave ventricular systolic dysfunction , leave ventricular hypertrophy ) , coronary heart disease ( symptomatic ischemia demonstrate diagnostic testing ) , myocardial infarction atrial thrombotic event within past 6 month , severe unstable angina , New York Heart Association Class III IV heart disease depress leave ventricular ejection fraction ( LVEF ; &lt; 50 % ) , clinically significant electrolyte abnormality ( e.g. , hypokalemia , hypomagnesemia , hypocalcemia ) , family history sudden unexplained death long QT syndrome Current treatment medication well know prolong QT interval History malignancy within previous 5 year , except appropriately treat nonmelanoma skin carcinoma , participant undergo potentially curative therapy evidence disease deem treat physician low risk recurrence Any disease , cardiovascular , pulmonary , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render participant high risk treatment complication . DiseaseSpecific Pathologic finding consistent smallcell neuroendocrine carcinoma prostate Treatment chemotherapy treatment castrationresistant prostate cancer Use opiate analgesic cancerrelated pain , include codeine dextropropoxyphene , currently time within 4 week Day 1 , Cycle 1 Any prior anticancer therapy Known untreated active central nervous system ( CNS ) metastases ( progress require anticonvulsant medication corticosteroid symptomatic control ) ; CT MRI scan brain perform screening require local health authority Any chronic therapy use food supplement strong CYP3A4/5 inducer sensitive CYP2D6 substrates narrow therapeutic window AbirateroneSpecific Uncontrolled hypertension ( systolic blood pressure ≥ 160 mmHg diastolic blood pressure ≥ 95 mmHg ) History pituitary adrenal dysfunction Atrial fibrillation cardiac arrhythmia require therapy IpatasertibSpecific Type 1 Type 2 diabetes mellitus require insulin study entry History inflammatory bowel disease ( e.g. , Crohn disease ulcerative colitis ) , active bowel inflammation ( e.g. , diverticulitis )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Metastatic Castrate-Resistant Prostate Cancer</keyword>
</DOC>